Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA | P62937 | 4/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23854867 | 1.00 | PPIA (0.36) | PPIAESR1ESR2SCN5ASCN2A | |
| SCHEMBL23854869 | 1.00 | PPIA (0.36) | PPIAESR1ESR2SCN5ASCN2A | |
| SCHEMBL21884443 | 0.87 | PPIA (0.38) | PPIAESR1ESR2MEN1KMT2A | |
| SCHEMBL21885717 | 0.82 | MRGPRX4 (0.41) | — | |
| SCHEMBL21884409 | 0.81 | PPIA (0.36) | PPIAMEN1KMT2A | |
| SCHEMBL21884474 | 0.80 | PPIA (0.36) | PPIA | |
| SCHEMBL23875082 | 0.79 | MAOA (0.36) | PPIASCN5ASCN2AMEN1KMT2A | |
| SCHEMBL21884360 | 0.77 | MEN1 (0.33) | PPIAMEN1KMT2APDK2 | |
| SCHEMBL23854877 | 0.76 | PPIA (0.39) | PPIAMEN1KMT2A | |
| SCHEMBL21884572 | 0.76 | TAS1R3 (0.33) | PPIAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2020061473-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | SLC19A1, SLC1A5, SLC1A2 | PPIA 1961/4885ESR1 4752/4885ESR2 3315/4885 |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | SNRPE, G3BP1, G3BP2 | PPIA 2399/4885ESR1 4321/4885ESR2 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.